ZBH

Healthcare

Zimmer Biomet

Price Chart

Market Data

Financials

XBRL · SEC EDGAR

2008–2025(18yr)

Revenue

Net Income

Free CF

Metric	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025Latest	YoY
Revenue	$4.1B	$4.1B	$4.2B	$4.5B	$4.5B	$4.6B	$4.7B	$6.0B	$7.7B	$7.8B	$7.9B	$8.0B	$7.0B	$7.8B	$6.9B	$7.4B	$7.7B	$8.2B	+7.2%
Gross Profit	$3.1B	$3.1B	$3.2B	$3.3B	$3.3B	$3.3B	$3.4B	$4.2B	$5.3B	$5.7B	$5.7B	$5.7B	$4.9B	$5.5B	$4.9B	$5.3B	$5.5B	$5.7B	+4.6%
Gross Margin	75.8%	75.8%	76.0%	74.8%	74.8%	72.2%	73.3%	70.0%	68.9%	72.7%	71.4%	71.8%	69.7%	70.1%	70.9%	71.8%	71.5%	69.7%	-1.8pp
Operating Income	$1.1B	$1.0B	$916.7M	$1.0B	$1.0B	$1.0B	$1.0B	$467.3M	$825.9M	$808.2M	$33.8M	$1.1B	-$87.8M	$780.1M	$696.3M	$1.3B	$1.3B	$1.1B	-14.6%
Operating Margin	26.4%	24.9%	21.7%	23.0%	23.4%	22.4%	22.1%	7.8%	10.8%	10.4%	0.4%	14.3%	-1.2%	10.0%	10.0%	17.3%	16.7%	13.3%	-3.4pp
Net Income	$848.6M	$717.4M	$596.9M	$760.8M	$755.0M	$761.0M	$720.1M	$147.0M	$305.9M	$1.8B	-$379.2M	$1.1B	-$138.9M	$401.6M	$231.4M	$1.0B	$903.8M	$705.1M	-22.0%
Net Margin	20.6%	17.5%	14.1%	17.1%	16.9%	16.5%	15.4%	2.5%	4.0%	23.2%	-4.8%	14.2%	-2.0%	5.1%	3.3%	13.8%	11.8%	8.6%	-3.2pp
Free Cash Flow	$788.1M	$1.0B	$1.1B	$1.1B	$1.0B	$863.1M	—	—	$1.4B	$1.4B	$1.6B	$1.4B	$1.1B	$1.3B	—	$1.3B	$1.3B	$1.5B	+13.7%
FCF Margin	19.1%	24.7%	26.4%	23.9%	23.2%	18.7%	—	—	18.9%	18.3%	20.0%	17.3%	15.5%	16.9%	—	17.5%	16.9%	17.9%	+1.0pp
EPS (Diluted)	$3.72	$3.32	$2.97	$4.03	$4.29	$4.43	$4.19	$0.77	$1.51	$8.90	$-1.86	$5.47	$-0.67	$1.91	$1.10	$4.88	$4.43	$3.55	-19.9%

Total Debt$6.9B

Cash & Equiv.$591.9M

Net Debt$6.3B

4 min read

1. THE BIG PICTURE

Zimmer Biomet is currently a story of internal friction versus external demand. While Zimmer Biomet concluded 2025 with 10.9% revenue growth fueled by its robotic platforms and specialized surgical implants, management is intentionally tempering its 2026 outlook to execute a fundamental shift in its U.S. commercial model. Zimmer Biomet is betting that moving to a direct, employee-based sales force will secure long-term market leadership, even if the transition creates near-term turbulence.

2. WHERE THE RISKS HIT HARDEST

The "global approach to sales force training" that Zimmer Biomet cites as a core competitive advantage (10-K Item 1) is currently its greatest point of vulnerability. The transition to a direct sales model threatens this strength because it risks the "loss of key personnel" and "diminished sales effectiveness" during the handoff from independent distributors (Risks). If these relationships fray, Zimmer Biomet’s ability to sell its high-margin "integrated solutions" like the ZBEdge Platform could be compromised.

Furthermore, Zimmer Biomet’s reliance on "extensive research and development" to maintain its competitive position (10-K Item 1) is increasingly constrained by its balance sheet. With $7.5 billion in total debt and $0.6 billion in near-term service obligations, Zimmer Biomet’s financial flexibility to fund the very innovation it relies on is restricted (Risks). This creates a cycle where debt obligations could slow the "rapid commercialization of new data solutions" required to stay ahead of peers like Stryker and Medtronic.

3. WHAT THE NUMBERS SAY TOGETHER

The financial data reveals a company with elite profitability but decelerating expectations. Zimmer Biomet maintains a 71.3% gross margin—the second-highest in its peer group—and converts 17.7% of revenue into free cash flow (XBRL). However, while Q4 2025 revenue grew by 10.9%, management’s 2026 organic growth guidance of 1.0% to 3.0% represents a sharp divergence from recent performance (8-K). This slowdown is not a result of market softening but is a deliberate "tempering" caused by the U.S. sales force reorganization (8-K).

The market appears skeptical of this transition; short interest stands at 4.9% of the float (Yahoo Finance). Despite this, Zimmer Biomet is aggressively returning capital, leading its peer group with a 4.6% buyback yield (Peer Benchmarking). This suggests management views the current share price as a disconnect from the underlying cash-generative power of the business.

4. IS IT WORTH IT AT THIS PRICE?

At a forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations of 10.3x, Zimmer Biomet trades at a massive discount to the peer median of 17.9x (Peer Benchmarking). The market is currently pricing in a long-term growth rate of just 0.5% (CAPM analysis). This valuation appears attractively valued given that Zimmer Biomet’s "S.E.T." category—comprising sports medicine and trauma—grew by 20.1% in the most recent quarter (8-K).

For this price to be "right," the sales force transition would have to result in a permanent loss of market share. However, if Zimmer Biomet merely achieves its guided 2026 organic growth of 1.0% to 3.0%, it would already be outperforming the market's pessimistic 0.5% implied growth rate. The primary risk that could justify this low multiple is the $7.5 billion debt load, which leaves little room for error if elective procedure volumes face a macro-driven decline.

5. WHAT WOULD CHANGE THIS VIEW?

Constructive if 2026 organic revenue growth exceeds the 3.0% upper bound of guidance, proving the sales force transition is not causing the feared level of disruption.
Cautious if the $0.6 billion in near-term debt obligations requires a reduction in R&DR&DResearch & Development — spending on creating new products or technologies spending or a suspension of the 4.6% buyback yield.

6. BOTTOM LINE

Structural Advantage: A high-margin portfolio of orthopedic implants deeply integrated with the proprietary ZBEdge robotic and data ecosystem.

Bottom Line: Zimmer Biomet is a highly profitable cash generator priced for a worst-case operational failure that its recent product momentum does not yet support.

Source: Synthesis · LLM Analysis

3 min read

1. Top 5 Material Risks

Sales Force Transformation: Zimmer Biomet is converting its U.S. sales force from independent distributors to employees. This transition risks operational disruptions, loss of key personnel, and diminished sales effectiveness, which could lead to lower net sales.
Debt Obligations: With $7.5 billion in total indebtedness as of December 31, 2025, Zimmer Biomet faces increased demands on cash resources. This debt limits Zimmer Biomet's ability to fund research and development, capital expenditures, and strategic acquisitions.
Manufacturing and Supply Chain: Manufacturing is concentrated in specific plants, and Zimmer Biomet has previously experienced interruptions—including those related to ERP system implementations—that negatively impacted product distribution and resulted in lost sales.
Intellectual Property Litigation: Zimmer Biomet is frequently involved in patent infringement actions. Adverse outcomes in these legal proceedings could result in significant monetary damages or royalty payments and restrict Zimmer Biomet's ability to sell current or future products.
Regulatory Compliance: Zimmer Biomet is subject to rigorous oversight by the FDA and international bodies. Non-compliance with quality systems or marketing regulations can lead to product recalls, bans, or the imposition of operating restrictions that materially harm financial results.

2. Company-Specific Risks

ERP System Integration: Challenges in consolidating and integrating enterprise resource planning (ERP) systems, such as the 2024 Americas transition, have disrupted order fulfillment, delayed invoicing, and caused a loss of customers and sales.
Product Portfolio Rationalization: Efforts to streamline operations and focus on strategic offerings may lead to transitional inefficiencies, including inventory imbalances and the loss of product breadth, which could reduce sales in affected categories.
Sterilization Constraints: Zimmer Biomet relies on a mix of internal and contract sterilization services. Financial constraints or capacity issues at sterilization suppliers—such as the 2024 bankruptcy of a supplier—can prevent Zimmer Biomet from meeting customer demand.
ZimVie Spinoff Liabilities: The spinoff of ZimVie Inc. and the subsequent divestiture of retained shares were based on specific factual assumptions; if these transactions fail to qualify for tax-free treatment, the resulting tax liability could be substantial.

3. Regulatory/Legal Risks

Healthcare Fraud and Abuse: Zimmer Biomet is subject to the False Claims Act, the Anti-Kickback Statute, and the Physician Payments Sunshine Act. Violations can result in exclusion from government programs like Medicare and Medicaid.
Data Privacy: Zimmer Biomet processes patient health data and is subject to evolving global privacy laws. Failure to comply with these regulations can lead to substantial civil or criminal penalties and private litigation.
Product Liability: Zimmer Biomet faces ongoing lawsuits alleging design defects or manufacturing flaws. These claims are costly to defend and can damage Zimmer Biomet's reputation, regardless of the outcome.
International Pricing Pressures: Initiatives like China’s volume-based procurement (VBP) and Italy’s “Pay Back” law for medical devices have resulted in reduced margins and required the renegotiation of distributor arrangements.

4. Financial Impact Map

Sales Force Transformation → Net Sales → Potential for sales coverage gaps and reduced productivity during the multi-year transition. Debt Obligations → Cash Flow from Operations → $0.6 billion in principal debt service obligations due within 12 months, reducing funds available for R&DR&DResearch & Development — spending on creating new products or technologies and capital expenditures. Manufacturing/ERP Interruptions → Net Sales → Disruptions in distribution and order fulfillment directly impact the ability to recognize revenue. Intellectual Property Litigation → Operating Expenses → Potential for significant monetary damages or royalty payments resulting from adverse legal outcomes. Product Portfolio Rationalization → Inventory/Asset Impairments → Risk of higher-than-expected inventory obsolescence and asset impairments as product lines are discontinued.

Source: 10-K Item 1A · LLM Analysis